DE69825906D1 - Verwendung von angiostatische steroide in photodynamischer therapie - Google Patents
Verwendung von angiostatische steroide in photodynamischer therapieInfo
- Publication number
- DE69825906D1 DE69825906D1 DE69825906T DE69825906T DE69825906D1 DE 69825906 D1 DE69825906 D1 DE 69825906D1 DE 69825906 T DE69825906 T DE 69825906T DE 69825906 T DE69825906 T DE 69825906T DE 69825906 D1 DE69825906 D1 DE 69825906D1
- Authority
- DE
- Germany
- Prior art keywords
- photodynamic therapy
- angiostatic steroids
- angiostatic
- steroids
- steriod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US895184 | 1997-07-16 | ||
US08/895,184 US5770592A (en) | 1991-11-22 | 1997-07-16 | Prevention and treatment of ocular neovascularization using angiostatic steroids |
PCT/US1998/012711 WO1999003503A1 (en) | 1997-07-16 | 1998-06-18 | The use of angiostatic steroids in photodynamic therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69825906D1 true DE69825906D1 (de) | 2004-09-30 |
DE69825906T2 DE69825906T2 (de) | 2005-09-01 |
Family
ID=25404127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69825906T Expired - Fee Related DE69825906T2 (de) | 1997-07-16 | 1998-06-18 | Verwendung von angiostatische steroide in photodynamischer therapie |
Country Status (13)
Country | Link |
---|---|
US (2) | US5770592A (de) |
EP (1) | EP1003553B1 (de) |
JP (1) | JP2001510170A (de) |
AT (1) | ATE274356T1 (de) |
AU (1) | AU734195B2 (de) |
BR (1) | BR9811012A (de) |
CA (1) | CA2296558A1 (de) |
DE (1) | DE69825906T2 (de) |
DK (1) | DK1003553T3 (de) |
ES (1) | ES2224412T3 (de) |
HK (1) | HK1028952A1 (de) |
PT (1) | PT1003553E (de) |
WO (1) | WO1999003503A1 (de) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1154691A4 (de) * | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | Gezielte transsklerale gesteuerte wirkstoffabgabe an die retina und choroidae |
WO2000041725A2 (en) * | 1999-01-15 | 2000-07-20 | Light Sciences Corporation | Therapeutic compositions for metabolic bone disorders or bone metastases |
CA2356532A1 (en) | 1999-01-15 | 2000-07-20 | Light Sciences Corporation | Noninvasive vascular therapy |
US6602274B1 (en) | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
EP1221918B1 (de) | 1999-10-21 | 2005-03-16 | Alcon Inc. | Medikamentenversorgung der sub-tenon |
ATE283013T1 (de) | 1999-10-21 | 2004-12-15 | Alcon Inc | Medikamentenzuführvorrichtung |
US7678836B2 (en) * | 1999-11-04 | 2010-03-16 | Fxs Ventures, Llc | Method for rendering a contact lens wettable |
CA2398901C (en) * | 2000-02-10 | 2010-11-16 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
AU5040101A (en) * | 2000-03-24 | 2001-10-15 | Novartis Ag | Improved treatment of neovascularization |
EP1570859A3 (de) * | 2000-03-24 | 2008-04-02 | Novartis AG | Verbesserte Behandlung von Neovaskularisation |
CA2446143C (en) * | 2000-05-19 | 2010-01-19 | Michael S. Berlin | Delivery system and method of use for the eye |
US8679089B2 (en) | 2001-05-21 | 2014-03-25 | Michael S. Berlin | Glaucoma surgery methods and systems |
US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
US7563255B2 (en) | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
JP4249611B2 (ja) * | 2001-07-23 | 2009-04-02 | アルコン,インコーポレイティド | 眼薬剤送致装置 |
PL204644B1 (pl) | 2001-07-23 | 2010-01-29 | Alcon | Okulistyczne urządzenie do podawania leków |
US7402577B2 (en) * | 2001-10-03 | 2008-07-22 | Merck & Co., Inc. | Androstane 17-beta-carboxamides as androgen receptor modulators |
CN1582156A (zh) * | 2001-11-09 | 2005-02-16 | 眼科技术药物公司 | 眼新血管疾病的治疗方法 |
US6723750B2 (en) | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
WO2004011460A2 (en) | 2002-07-24 | 2004-02-05 | Qlt, Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
WO2004011544A1 (en) * | 2002-07-29 | 2004-02-05 | Ast Products, Inc. | Ophtalmic compositions |
US6828356B2 (en) * | 2002-07-29 | 2004-12-07 | Ast Products, Inc. | Preparation of ophthalmic compositions |
US6806364B2 (en) * | 2002-07-29 | 2004-10-19 | Ast Products, Inc. | Ophthalmic compositions |
PL375024A1 (en) * | 2002-08-05 | 2005-11-14 | Alcon, Inc. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
DE10238310A1 (de) * | 2002-08-21 | 2004-03-04 | Erich Jaeger Gmbh | Elektrodenanordnung |
CA2500877A1 (en) * | 2002-10-03 | 2004-04-15 | Light Sciences Corporation | Excitation of photoreactive compounds in eye tissue |
WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
WO2004073607A2 (en) * | 2003-02-20 | 2004-09-02 | Alcon, Inc. | Use of steroids to treat ocular disorders |
EP1594511A2 (de) * | 2003-02-20 | 2005-11-16 | Alcon, Inc. | Glucocorticoid-formulierungen zur behandlung von pathologischer angiogenese im auge |
KR20060019579A (ko) * | 2003-06-13 | 2006-03-03 | 알콘, 인코퍼레이티드 | 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제 |
EP1635842A4 (de) * | 2003-06-20 | 2007-04-04 | Alcon Inc | Behandlung von amd mit einer kombination von inhaltsstoffen |
MXPA05011517A (es) * | 2003-07-10 | 2005-12-12 | Alcon Inc | Dispositivo para el suministro de medicamentos oftalmicos. |
US7585517B2 (en) * | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
CN1852700A (zh) * | 2003-09-23 | 2006-10-25 | 爱尔康公司 | 曲安奈德和醋酸阿奈可他注射用制剂 |
WO2005072744A1 (ja) * | 2004-02-02 | 2005-08-11 | Yuichi Kaji | 硝子体の可視化剤 |
CN1980929A (zh) * | 2004-02-24 | 2007-06-13 | 比奥阿克松医疗技术股份有限公司 | 4-取代哌啶衍生物 |
US20050239760A1 (en) * | 2004-04-23 | 2005-10-27 | Alcon, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
JP2008514645A (ja) | 2004-09-24 | 2008-05-08 | アールエフイー ファーマ エルエルシー | 眼疾患およびその他の疾患の局所的処置のためのcaiに基づくシステムおよび方法 |
US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
WO2006086750A1 (en) * | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
EP2292672B1 (de) | 2005-05-25 | 2018-05-09 | CIS Pharma AG | Bioverträgliche Polymere und Copolymere mit Aminosäuren in der Seitenkette |
EP2468318A1 (de) * | 2005-07-12 | 2012-06-27 | DMI Biosciences, Inc. | Verfahren und Produkte zur Behandlung von Erkrankungen |
WO2007014327A2 (en) | 2005-07-27 | 2007-02-01 | University Of Florida Research Foundation, Inc. | Small compounds that correct protein misfolding and uses thereof |
US7758778B2 (en) * | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
US7261529B2 (en) * | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
ES2681656T3 (es) | 2005-09-07 | 2018-09-14 | Amgen Fremont Inc. | Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1) |
AU2006304553A1 (en) * | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Method for treating primary and secondary forms of glaucoma |
US20080125406A1 (en) * | 2005-10-14 | 2008-05-29 | Robin Alan L | Method for Treating Primary and Secondary Forms of Glaucoma |
WO2007047626A1 (en) * | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis |
CA2628570A1 (en) | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
EP2329821B1 (de) | 2005-11-29 | 2012-08-22 | GlaxoSmithKline LLC | Behandlung von neovaskulären Augenerkrankungen, wie z.B. Maculadegeneration, angioiden Streifen, Uveitis und Makulaödemen |
CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
KR101520408B1 (ko) | 2006-03-23 | 2015-05-14 | 산텐 세이야꾸 가부시키가이샤 | 혈관 투과성-관련 질환 또는 상태를 위한 제형 및 방법 |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US20090181933A1 (en) * | 2008-01-11 | 2009-07-16 | Bingaman David P | Use of steroids to treat persons suffering from ocular disorders |
JP2011513002A (ja) | 2008-03-05 | 2011-04-28 | イバンティス インコーポレイテッド | 緑内障を治療する方法及び器具 |
EP2278978B1 (de) | 2008-05-28 | 2015-09-02 | ReveraGen BioPharma, Inc. | Nichthormonale steroide modulatoren von nf-kb zur krankheitsbehandlung |
US8372036B2 (en) | 2009-05-06 | 2013-02-12 | Alcon Research, Ltd. | Multi-layer heat assembly for a drug delivery device |
IN2012DN00352A (de) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
ES2554688T3 (es) | 2009-06-22 | 2015-12-22 | Ampio Pharmaceuticals, Inc. | Procedimiento de tratamiento de enfermedades |
EP2445350A4 (de) * | 2009-06-22 | 2012-12-26 | Dmi Acquisition Corp | Verfahren und produkte zur behandlung von erkrankungen |
AU2010271274B2 (en) | 2009-07-09 | 2015-05-21 | Alcon Inc. | Single operator device for delivering an ocular implant |
AU2010271218B2 (en) | 2009-07-09 | 2017-02-02 | Alcon Inc. | Ocular implants and methods for delivering ocular implants into the eye |
WO2011039648A1 (en) | 2009-09-30 | 2011-04-07 | Glaxo Wellcome Manufacturing Pte Ltd. | Methods of administration and treatment |
US8177747B2 (en) | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
US9198921B2 (en) | 2010-04-05 | 2015-12-01 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
US20120283557A1 (en) | 2011-05-05 | 2012-11-08 | Berlin Michael S | Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses |
US9133082B2 (en) | 2011-06-14 | 2015-09-15 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
EP2768307B1 (de) | 2011-10-19 | 2020-03-18 | Bikam Pharmaceuticals, Inc. | Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür |
AU2012346214B2 (en) | 2011-11-30 | 2017-09-14 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
WO2013081642A1 (en) | 2011-12-01 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
EP2934546A4 (de) | 2012-12-19 | 2016-06-22 | Ampio Pharmaceuticals Inc | Verfahren zur krankheitsbehandlung |
WO2016011056A1 (en) | 2014-07-14 | 2016-01-21 | Ivantis, Inc. | Ocular implant delivery system and method |
US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
WO2017004205A1 (en) | 2015-06-29 | 2017-01-05 | Reveragen Biopharma, Inc. | NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE |
EP4265231A3 (de) | 2015-08-14 | 2023-12-20 | Alcon Inc. | Augenimplantat mit drucksensor |
US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
US10537567B2 (en) | 2017-07-11 | 2020-01-21 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
JP2024503989A (ja) | 2021-01-11 | 2024-01-30 | アルコン インコーポレイティド | 粘弾性体送達のためのシステム及び方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
ATE190623T1 (de) * | 1990-06-11 | 2000-04-15 | Alcon Lab Inc | Verwendung von steroiden zur inhibierung von angiogenesis |
CA2185644C (en) * | 1994-03-14 | 2011-04-12 | Joan W. Miller | Use of green porphyrins in ocular diagnosis and therapy |
-
1997
- 1997-07-16 US US08/895,184 patent/US5770592A/en not_active Expired - Fee Related
-
1998
- 1998-06-18 JP JP2000502798A patent/JP2001510170A/ja active Pending
- 1998-06-18 CA CA002296558A patent/CA2296558A1/en not_active Abandoned
- 1998-06-18 EP EP98931367A patent/EP1003553B1/de not_active Expired - Lifetime
- 1998-06-18 ES ES98931367T patent/ES2224412T3/es not_active Expired - Lifetime
- 1998-06-18 DE DE69825906T patent/DE69825906T2/de not_active Expired - Fee Related
- 1998-06-18 PT PT98931367T patent/PT1003553E/pt unknown
- 1998-06-18 DK DK98931367T patent/DK1003553T3/da active
- 1998-06-18 US US09/445,237 patent/US6297228B1/en not_active Expired - Fee Related
- 1998-06-18 WO PCT/US1998/012711 patent/WO1999003503A1/en active IP Right Grant
- 1998-06-18 AU AU81515/98A patent/AU734195B2/en not_active Ceased
- 1998-06-18 AT AT98931367T patent/ATE274356T1/de not_active IP Right Cessation
- 1998-06-18 BR BR9811012-8A patent/BR9811012A/pt not_active Application Discontinuation
-
2000
- 2000-11-22 HK HK00107465A patent/HK1028952A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1003553B1 (de) | 2004-08-25 |
ES2224412T3 (es) | 2005-03-01 |
PT1003553E (pt) | 2004-10-29 |
US6297228B1 (en) | 2001-10-02 |
US5770592A (en) | 1998-06-23 |
WO1999003503A1 (en) | 1999-01-28 |
ATE274356T1 (de) | 2004-09-15 |
HK1028952A1 (en) | 2001-03-16 |
EP1003553A1 (de) | 2000-05-31 |
CA2296558A1 (en) | 1999-01-28 |
BR9811012A (pt) | 2000-10-17 |
AU734195B2 (en) | 2001-06-07 |
DE69825906T2 (de) | 2005-09-01 |
DK1003553T3 (da) | 2004-09-20 |
JP2001510170A (ja) | 2001-07-31 |
AU8151598A (en) | 1999-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69825906D1 (de) | Verwendung von angiostatische steroide in photodynamischer therapie | |
AU2207000A (en) | Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia | |
DK1039912T3 (da) | Angiostatiske midler og præparater til behandling af GLC1A-glaukom | |
ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
ATE324119T1 (de) | Verwendung von saccharid-konjugaten | |
DE69434491D1 (de) | Hautpflaster enthaltend testosteron und gegebenenfalls estrogen | |
ATE424211T1 (de) | Therapeutische verwendung von sapogeninen | |
DE60040753D1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
DE60216300D1 (de) | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption | |
ATE247709T1 (de) | 3'utr des menschliches prohibitin-gens | |
ATE442861T1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
TR199901003T2 (xx) | Ast�m tedavisi i�in loratadin ve bir dekonjestan i�eren bile�im. | |
DE69705421D1 (de) | 15-fluoro-prostaglandine als augendrucksenkende mittel | |
DE69729004D1 (de) | Photodynamische therapie zur behandlung von osteosrthritis | |
ATE306270T1 (de) | Verwendung von fulvestrant in der behandlung von resistentem brustkrebs | |
DE69710333T2 (de) | Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie | |
DE69912304D1 (de) | Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen | |
TW200507858A (en) | Formulations of glucocorticoids to treat pathologic ocular angiogenesis | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
DE69821227D1 (de) | Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen | |
DE60319719D1 (de) | Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie | |
DK0900085T3 (da) | Behandling af overdreven aggression med olanzapin | |
ATE271878T1 (de) | Verwendung von protein h als zytostattischer wirkstoff | |
PT1169026E (pt) | Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular | |
UA43728A (uk) | Спосіб лікування раку передміхурової залози |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |